Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial

Inclusion Criteria: * Subjects \> 60 years of age * Diagnosed case (PCR test for COVID-19 if available) or COVID-19 clinical symptoms (defined as fever, dry cough, dyspnea, chest radiography with compatible findings with COVID-19) * Lymphocyte count ≥ 0.2 x 103/µL and ≤1.0 x 103/µL. * Neutrophil count ≥ 1.8 x 103/µL, platelets ≥ 150 x 103/µL. * ROX ≥ 10 index * Signed informed consent document * Willing to comply with the lenalidomide Risk Minimization Program (Pregnancy Prevention Program approved) Exclusion Criteria: * Absolute contraindication of lenalidomide use or hypersensitivity to the active ingredient or any of the excipients. * Active neoplasia * Previous autoimmune disease * Concurrent infection of HBV, HCV or tuberculosis. * Aspartate transaminase (AST) or alanine transaminase (ALT) \> 3 times the upper limit of normal (ULN). * Bilirubin levels \> 1.5 times the ULN * Renal impairment with an estimated GF \< 30ml/min * Venous thromboembolism events within the previous 3 years * Significant active heart disease within the previous 6 months, including congestive heart failure (class II-IV NYHA), unstable angina or myocardial infarctions * Sexually active subjects who refuse the lenalidomide Risk Minimization Program * Inability to comply with the working protocol under the responsible health professional opinion.